2025-522335-34-00招募中1 期
(22597) A study to learn about how safe nitroglycerin is and how it affects the body when taken along with nurandociguat in people with coronary artery disease.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Bayer AG
- 入组人数
- 26
- 试验地点
- 4
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Therapeutic Area Head
Scientific
Bayer AG
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A study to learn how safe nurandociguat is when taken with sildenafil in men with arterial hypertension.Chronic Kidney Disease2025-522336-14-00Bayer AG36
已完成
1 期
Study is designed to assess the safety and tolerability of ceralasertib at increasing doses in combination with other anti-cancer treatment in patients with advanced tumours2023-505006-41-00AstraZeneca AB100
已完成
1 期
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human body.2023-506114-49-00Cerevance Inc.64
招募中
1 期
A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabetes.2024-519533-38-00Novo Nordisk A/S96
招募中
1 期
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.2025-522243-17-00Philogen S.p.A.96